Marianne D. De Backer, MSc, PhD, MBA’s Post

View profile for Marianne D. De Backer, MSc, PhD, MBA, graphic

CEO Vir Biotechnology, Inc. Board Member. Passionate about making a difference for patients.

I am incredibly proud to share that Vir Biotechnology, Inc. has received IND clearance and Fast Track designation from the U.S. FDA for our combination therapy, tobevibart and elebsiran, for the treatment of chronic #hepatitis delta infection. This significant milestone, along with the encouraging preliminary data from our Phase 2 SOLSTICE trial, underscores the potential of this treatment to transform the landscape for people living with this severe and life-threatening disease. #PatientsareWaiting

TOOCHUKWU JOHNMARK

CEO at ADIN. Pioneering sustainable solutions within the energy and recycling sectors.

2w

That's a good news

Like
Reply
Aniket Badkar

Director, Formulation and Drug Product Development at Vir Biotechnology, Inc.

3w

#PatientsareWaiting

Muthukrishnan Ramachandran

Training Officer @ NTTF | Data Science, AI | Political and Public PolicyAnalyst | Public Speaker | Voulunteer in Non Profit activities | Public Health Researcher

2w

Congratulations Dr. Marianne an team 💐🌸

Like
Reply
Anita Campos M Silva

Clinical Research and Development, Evidence Generation & Medical Affairs Leader | Innovator in Infectious Diseases, Rare Diseases, Cell Therapy and Gene Therapy | Medical Director Med.IQ | Infectious Diseases Physician

3w

That’s incredible news for the hepatitis delta patients !

Excellent progress - congrats (gefeliciteerd :-) Marianne and team!

Carol L. Brosgart, MD

Senior Advisor on Science and Policy, VHAC at the CDC Foundation and the Division of Viral Hepatitis at CDC

3w

Great progress, Marianne!

See more comments

To view or add a comment, sign in

Explore topics